Investigational Drug Information for Vadadustat
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Vadadustat?
Vadadustat is an investigational drug.
There have been 29 clinical trials for Vadadustat.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2016.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Mitsubishi Tanabe Pharma Corporation, and Otsuka Pharmaceutical Development & Commercialization, Inc.
There are twenty-two US patents protecting this investigational drug and two hundred and thirty-two international patents.
Summary for Vadadustat
| US Patents | 22 |
| International Patents | 232 |
| US Patent Applications | 79 |
| WIPO Patent Applications | 55 |
| Japanese Patent Applications | 20 |
| Clinical Trial Progress | Phase 3 (2016-02-01) |
| Vendors | 39 |
Recent Clinical Trials for Vadadustat
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease | Akebia Therapeutics | Phase 3 |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents | Akebia Therapeutics | Phase 3 |
| Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | Akebia Therapeutics | Phase 3 |
Clinical Trial Summary for Vadadustat
Top disease conditions for Vadadustat
Top clinical trial sponsors for Vadadustat
US Patents for Vadadustat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Vadadustat | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Vadadustat | See Plans and Pricing | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | See Plans and Pricing |
| Vadadustat | See Plans and Pricing | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| Vadadustat | See Plans and Pricing | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | Akebia Therapeutics, Inc. (Cambridge, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Vadadustat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Vadadustat | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| Vadadustat | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| Vadadustat | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| Vadadustat | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
